Iambic Therapeutics Files Form S-1 for Nasdaq IPO Under IAM
Iambic Therapeutics filed a Form S-1 with the SEC to list on Nasdaq under IAM, backed by Nvidia and Coatue, with $207.9M in cash and clinical HER2 data.
AI drug discovery
Pharma Giants Race to Harness AI — What It Means for Drug Stocks
From protein folding to clinical trials, AI is transforming drug discovery. Novo Nordisk’s OpenAI deal is the latest signal for pharma investors.